Janus Henderson Group PLC Takes Position in Septerna, Inc. (NASDAQ:SEPN)

Janus Henderson Group PLC acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 1,096,302 shares of the company's stock, valued at approximately $25,111,000. Janus Henderson Group PLC owned 2.47% of Septerna at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in SEPN. Tower Research Capital LLC TRC purchased a new position in shares of Septerna during the 4th quarter worth approximately $25,000. New York State Common Retirement Fund purchased a new position in Septerna in the 4th quarter valued at approximately $32,000. Legal & General Group Plc purchased a new position in Septerna in the 4th quarter valued at approximately $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna during the fourth quarter worth $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Septerna during the fourth quarter worth $52,000.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald raised their price objective on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Wells Fargo & Company raised their price objective on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th.

Septerna Stock Up 0.6%

Septerna stock traded up $0.06 during midday trading on Wednesday, hitting $9.48. The stock had a trading volume of 170,484 shares, compared to its average volume of 713,638. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99. The business has a fifty day moving average price of $6.55 and a 200 day moving average price of $14.05.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The firm had revenue of $0.22 million during the quarter. On average, sell-side analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Insider Activity

In other Septerna news, Director Alan Ezekowitz acquired 7,491 shares of Septerna stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average cost of $6.35 per share, for a total transaction of $47,567.85. Following the completion of the transaction, the director now owns 24,911 shares in the company, valued at approximately $158,184.85. This represents a 43.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Gil M. Labrucherie bought 5,000 shares of the business's stock in a transaction on Friday, February 21st. The stock was purchased at an average price of $5.85 per share, with a total value of $29,250.00. Following the completion of the transaction, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at $175,500. This trade represents a 20.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 63,846 shares of company stock valued at $381,815. 4.30% of the stock is currently owned by insiders.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.